Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Sees Significant Decline in Short Interest

Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) was the recipient of a large decrease in short interest during the month of January. As of January 15th, there was short interest totaling 19,594 shares, a decrease of 54.7% from the December 31st total of 43,229 shares. Approximately 3.2% of the shares of the stock are sold short. Based on an average daily volume of 107,054 shares, the days-to-cover ratio is currently 0.2 days. Based on an average daily volume of 107,054 shares, the days-to-cover ratio is currently 0.2 days. Approximately 3.2% of the shares of the stock are sold short.

Analyst Upgrades and Downgrades

BDRX has been the subject of several research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biodexa Pharmaceuticals in a research note on Monday, December 29th. Wall Street Zen raised shares of Biodexa Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, January 23rd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

Biodexa Pharmaceuticals Stock Performance

BDRX opened at $1.84 on Friday. The stock’s 50 day simple moving average is $3.50 and its 200 day simple moving average is $5.65. Biodexa Pharmaceuticals has a 1 year low of $1.80 and a 1 year high of $92.00.

Biodexa Pharmaceuticals Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.